Related Articles
Test
test test
Continue reading
Eli Lilly’s new diabetes drug continues to show promise as an obesity treatment
Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.
Continue reading
Cramer greenlights beaten-down tech stocks, says Target’s inventory woes suggest inflation is peaking
“The real greenlight here is on the beaten down tech,” the “Mad Money” host said.
Continue reading